Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icotinib Hydrochloride Cream in Mild to Moderate Psoriasis
NCT02801435Phase 1Completed
- Sponsor
- Betta Pharmaceuticals
- Start
- Sep 2016
- Primary completion
- Jun 2017
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of icotinib in psoriasis (8 arms), sponsored by Betta Pharmaceuticals. Primary endpoint: Safety in patients with mild to moderate psoriasis at 28 days. Started Sep 2016; status: completed.
02
Drugs
icotinib
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT02801435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02801435.